Purchase Short-Term Access

Review: Oral drugs for type 2 diabetes, alone or in combination, have different relative benefits and harms for surrogate endpoints

Juan Pablo Domecq, MD; Gabriela Prutsky, MD; Victor M. Montori, MD

Annals of Internal Medicine 2011;155:JC2-4. doi:10.7326/0003-4819-155-4-201108160-02004

Purchase Online access to this article for 24 hours

Annals of Internal Medicine

Forgot Your Password?

to gain full access to the content and tools.

Learn more about subscription options

Forgot your password?

Enter your username and email address. We'll send you a reminder to the email address on record.

Username* (Required)

Email Address* (Required)